Clarus Therapeutics Holdings Inc (CRXTQ)

OTC Markets
Currency in USD
0.01
0.00(0.00%)
Delayed Data

CRXTQ Income Statement

Advanced Income Statement
Period Ending:
2007
31/12
2008
31/12
2009
31/12
2012
31/12
2013
31/12
2019
31/12
2020
31/12
2021
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa-6.3713.96
Total Revenues Growth
aa.aaaa.aaaa.aaaa.aaaa.aa--+119.14%
Cost Of Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa-8.692.72
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa--2.3211.24
Gross Profit Growth
aa.aaaa.aaaa.aaaa.aaaa.aa--+584.77%
Gross Profit Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa--36.4%80.51%
Other Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa17.8844.8650.97
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-17.88-47.18-39.73
Operating Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+21.37%-163.91%+15.78%
EBIT Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa--740.73%-284.67%
Net Interest Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa-23.79-15.37-15.89
Net Interest Expenses Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-1,864.32%+35.39%-3.41%
Interest Expense, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-23.87-15.39-15.9
Interest And Investment Income
aa.aaaa.aaaa.aaaa.aaaa.aa0.080.030
Other Non Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa0.0166.8912.51
EBT, Excl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-41.654.35-43.12
Gain (Loss) On Sale Of Assets
aa.aaaa.aaaa.aaaa.aaaa.aa---
Other Unusual Items, Total
aa.aaaa.aaaa.aaaa.aaaa.aa--2.5
EBT, Incl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-41.654.35-40.62
EBT, Incl. Unusual Items Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-64.06%+110.43%-1,034.8%
EBT, Incl. Unusual Items Margin
aa.aaaa.aaaa.aaaa.aaaa.aa-68.22%-291.02%
Income Tax Expense
aa.aaaa.aaaa.aaaa.aaaa.aa---
Net Income to Company
aa.aaaa.aaaa.aaaa.aaaa.aa-41.654.35-40.62
Minority Interest
aa.aaaa.aaaa.aaaa.aaaa.aa---
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-41.654.35-40.62
Net Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-64.06%+110.43%-1,034.8%
Net Income Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-68.22%-291.02%
Preferred Dividend and Other Adjustments
aa.aaaa.aaaa.aaaa.aaaa.aa13.5914.68-0.41
Net Income to Common Excl. Extra Items
aa.aaaa.aaaa.aaaa.aaaa.aa-55.24-10.34-40.21
Basic EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-63.48-1.21-5.72
Basic EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+23.18%+98.09%-372.07%
Diluted EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-63.48-8.2-5.72
Diluted EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+23.18%+87.08%+30.25%
Basic Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa0.878.537.03
Diluted Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa0.878.537.03
Dividend Per Share
aa.aaaa.aaaa.aaaa.aaaa.aa---
Dividend Per Share Growth
aa.aaaa.aaaa.aaaa.aaaa.aa---
EBITDA
aa.aaaa.aaaa.aaaa.aaaa.aa-17.87-47.16-39.71
EBITDA Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+21.34%-163.87%+15.8%
EBITDA Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa--740.45%-284.5%
EBIT
aa.aaaa.aaaa.aaaa.aaaa.aa-17.88-47.18-39.73
* In Millions of USD (except for per share items)